ArticleScience advances2022
Human genetics uncovers
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Meta-evolutionary exome analysis identifies novel type 2 diabetes mellitus genes in the UK Biobank and all of us.PLoS genetics · 2025Pooled it
- Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.Nature communications · 2025Pooled it
- Article
- The central role of the β-cell in diabetes: from monogenic forms to type 1, type 2, and gestational diabetes.Reviews in endocrine & metabolic disorders · 2026Review
- [Genetic Susceptibility to Metabolic Syndrome: A Comparative Overview of the Mexican Population in a Global Context].Revista medica del Instituto Mexicano del Seguro Social · 2026Review
- The Impact of Maternal Obesity and Diabetes on the Development of Congenital Heart Defects (CHDs) in Offspring: A Narrative Review.Metabolites · 2026Review
- Biocompatible ligand balancing in transition metal coordination enables benign in-cell protein arylation.Nature chemistry · 2026Article
- Mexico City Prospective Study: cohort profile update.BMJ medicine · 2026Article
- Complete loss of SLC30A8 in humans improves glucose metabolism and beta cell function.Diabetologia · 2025Article
- The role of the beta cell in type 2 diabetes: new findings from the last 5 years.Diabetologia · 2025Review
- Population-scale gene-based analysis of whole-genome sequencing provides insights into metabolic health.Nature genetics · 2025Article
- MAP3K15 facilitates multiple viral genes expression in crustaceans via Dorsal-CC-CL-STAT axis besides the JNK/P38 pathway.PLoS pathogens · 2025Article
- Article
- Modified pegRNAs mitigate scaffold-derived prime editing by-products.Nature communications · 2025Article
- Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson's disease.Cell reports · 2025Article
- Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis.Nature genetics · 2025Article
- Longitudinal clinical and proteomic diabetes signatures in women with a history of gestational diabetes.JCI insight · 2024Article
- Understanding the Genetic Landscape of Gestational Diabetes: Insights into the Causes and Consequences of Elevated Glucose Levels in Pregnancy.Metabolites · 2024Review
- Article
- Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 9 institutions in 11 countries.
Abhishek NagCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-4638-2433
Ryan S DhindsaCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.ORCID 0000-0002-8965-0813
Jonathan MitchellCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Chirag VasavdaCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.ORCID 0000-0003-4558-4698
Andrew R HarperCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Dimitrios VitsiosCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-8939-5445
Andrea AhnmarkBioscience Metabolism, Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0001-8932-4631
Bilada BilicanDiscovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-3057-2654
Katja Madeyski-BengtsonDiscovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Bader ZarroukiBioscience Metabolism, Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Anthony W ZoghbiCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
Quanli WangCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
Katherine R SmithCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-0329-5938
Jesus Alegre-DíazFaculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, 4360 Ciudad de México, Mexico.ORCID 0000-0001-9390-3871
Pablo Kuri-MoralesFaculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, 4360 Ciudad de México, Mexico.ORCID 0000-0002-0704-9507
Jaime BerumenFaculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, 4360 Ciudad de México, Mexico.ORCID 0000-0001-6707-3317
Roberto Tapia-ConyerFaculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, 4360 Ciudad de México, Mexico.ORCID 0000-0003-3814-2904
Jonathan EmbersonNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, England, UK.ORCID 0000-0001-7792-9422
Jason M TorresNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, England, UK.ORCID 0000-0002-7537-7035
Rory CollinsNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, England, UK.ORCID 0000-0001-8288-8602
David M SmithEmerging Innovations, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0001-6831-280X
Benjamin ChallisTranslational Science and Experimental Medicine, Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-1130-2851
Dirk S PaulCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-8230-0116
Mohammad Bohlooly-YDiscovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Mike SnowdenDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
David BakerBioscience Metabolism, Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-8020-3275
Regina Fritsche-DanielsonEarly CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-0582-6429
Menelas N PangalosBioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0001-9783-0956
Slavé PetrovskiCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-1527-961X
AstraZeneca (Australia) · AUAstraZeneca (South Korea) · KRAstraZeneca (Finland) · FIUniversidad Nacional Autónoma de México · MXAstraZeneca (Japan) · JPUniversity of Oxford · GBAstraZeneca (Poland) · PLAstraZeneca (Switzerland) · CHThe University of Melbourne · AU
Funding
Training in Schizophrenia and Psychotic Disorders: From Animal Models to PatientsT32MH018870 · NIMH · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Guillermo Horga, Christoph Kellendonk · 1988 to 2026
$9.8MBritish Heart Foundation CH/12/2/29428British Heart Foundation CH/1996001/9454British Heart Foundation RG/13/13/30194British Heart Foundation RG/18/13/33946Medical Research Council G0300622Medical Research Council MC_EX_G0801669Medical Research Council MC_PC_12027Medical Research Council MC_PC_12028Medical Research Council MC_PC_12029Medical Research Council MC_U137686854Medical Research Council MC_UU_00017/2Medical Research Council MC_UU_00017/3NIMH NIH HHS T32 MH018870Wellcome Trust 058299
Abstract
We performed collapsing analyses on 454,796 UK Biobank (UKB) exomes to detect gene-level associations with diabetes. Recessive carriers of nonsynonymous variants in
Indexed as
Diabetes Mellitus, Type 2MAP Kinase Kinase KinasesGenetic Predisposition to DiseaseHumansMonocarboxylic Acid TransportersObesityProspective StudiesMAP3K15 protein, humanMAP Kinase Kinase KinasesMonocarboxylic Acid TransportersSLC16A11 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.